Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Thyroid cancer: what stands out in the ASCO 2026 guideline?
- NGS is no longer optional – it drives treatment decisions
- Lenvatinib remains the preferred first-line in RAI-refractory DTC
- Cabozantinib – standard second-line
- RET / NTRK fusions – should be targeted before MKIs
- BRAF V600E – a distinct pathway (critical in ATC)
- ATC is now managed in a molecularly stratified way
- Immunotherapy is limited – not routine in most settings
- Chemotherapy – nearly out of the game
- PDTC/DHGTC – still a gray zone, but better defined
This is no longer about choosing drugs. It’s about choosing biology.”
Title: Systemic Treatment of Thyroid Cancer: ASCO Guideline
Authors: Nabil F. Saba, Nofisat Ismaila, Douglas Adkins, Nishant Agrawal, Neil Akhave, Erik S. Blomain, Maria E. Cabanillas, Amy Chen, Thomas J. Galloway, Guilherme Harada, Dapeng Li, Salem I. Noureldine, Joe Scharpf, Lova L. Sun, Mei Tang, Lori Wirth, Francis Worden, Dan P. Zandberg, and Beth M. Beadle.
Other articles featuring Ahmet Dirican on OncoDaily.
